Quick Summary:
As the healthcare industry continues to evolve, the global Focal Segmental Glomerulosclerosis (FSGS) market is projected to escalate to $20.1 billion by 2030, indicating substantial growth potential that can't be ignored. In an industrial climate that demands in-depth knowledge of prevailing developments and insights, having a comprehensive market research report at your disposal is not just an advantage, it becomes a necessity.
Our detailed FSGS Market report scrutinizes various segments such as primary and secondary, provide the essential trends and growth forecasts to help you better determine where the opportunities lie. Furthermore, it examines the budding markets of powerhouses like the U.S and China, alongside promising regions such as Japan, Canada, and Germany. You will also gain exclusive insights about top competitors, fostering an in-depth understanding of the competitive landscape. Lastly, our report ensures you stay updated with complimentary year-long updates and access to our extensive digital archives and research platform, keeping your business strategies aligned with the ever-evolving market trends.
Global Focal Segmental Glomerulosclerosis Market to Reach $20.1 Billion by 2030
The global market for Focal Segmental Glomerulosclerosis estimated at US$12 Billion in the year 2022, is projected to reach a revised size of US$20.1 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2022-2030. Primary, one of the segments analyzed in the report, is projected to record 6.8% CAGR and reach US$16.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Secondary segment is readjusted to a revised 6.4% CAGR for the next 8-year period.
The U.S. Market is Estimated at $3.6 Billion, While China is Forecast to Grow at 6.1% CAGR
The Focal Segmental Glomerulosclerosis market in the U.S. is estimated at US$3.6 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$3.5 Billion by the year 2030 trailing a CAGR of 6.1% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.8% and 5.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.3% CAGR.Select Competitors (Total 41 Featured) -
- AbbVie, Inc.
- AstraZeneca PLC
- ChemoCentryx, Inc.
- GlaxoSmithKline PLC
- Novartis AG
- Pfizer, Inc.
- Retrophin, Inc.
- Sanofi SA
- Teva Pharmaceutical Industries Ltd.
- Variant Pharmaceuticals, Inc.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and the publisher's Research Platform
- Complimentary updates for one year
What is the estimated value of the Global Market for Focal Segmental Glomerulosclerosis?
What is the growth rate of the Global Market for Focal Segmental Glomerulosclerosis?
What is the forecasted size of the Global Market for Focal Segmental Glomerulosclerosis?
Who are the key companies in the Global Market for Focal Segmental Glomerulosclerosis?
| Report Attribute | Details |
|---|---|
| No. of Pages | 194 |
| Published | December 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 12 Billion |
| Forecasted Market Value ( USD | $ 20.1 Billion |
| Compound Annual Growth Rate | 6.7% |
| Regions Covered | Global |
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- AbbVie, Inc.
- AstraZeneca PLC
- ChemoCentryx, Inc.
- GlaxoSmithKline PLC
- Novartis AG
- Pfizer, Inc.
- Retrophin, Inc.
- Sanofi SA
- Teva Pharmaceutical Industries Ltd.
- Variant Pharmaceuticals, Inc.
